Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC003619 | Panoply™ Human CREB1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC003619 | Panoply™ Human CREB1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2308 | Human CREB1 Knockout Cell Line-HEK293T | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04187Z | Human CREB1 adenoviral particles | Inquiry |
| LV00243Z | Human CREB1 lentiviral particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH269293 | shRNA set against Rat CREB1 (NM_031017.1) | Inquiry |
| SHG138785 | shRNA set against Rat Creb1(NM_134443.1) | Inquiry |
| SHG139123 | shRNA set against Rat Creb1(NM_031017.1) | Inquiry |
| SHG139165 | shRNA set against Mouse Creb1(NM_133828.2) | Inquiry |
| SHG139219 | shRNA set against Mouse Creb1(NM_009952.2) | Inquiry |
| SHG198015 | shRNA set against Human CREB1(NM_004379.3) | Inquiry |
| SHH269285 | shRNA set against Human CREB1 (NM_004379.3) | Inquiry |
| SHH269289 | shRNA set against Mouse CREB1 (NM_133828.2) | Inquiry |
| SHW004963 | shRNA set against Chicken CREB1 (NM_204450) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB166438 | Chicken CREB1 ORF Clone (NM_204450) | Inquiry |
| CDFG018154 | Mouse Creb1 cDNA Clone(NM_001037726.1) | Inquiry |
| CDFL003075 | Mouse Creb1 cDNA Clone(NM_009952.2) | Inquiry |
| CDFR012493 | Rat Creb1 cDNA Clone(NM_031017.1) | Inquiry |
| CDFR014212 | Rat Creb1 cDNA Clone(NM_134443.1) | Inquiry |
| MiUTR1M-03310 | CREB1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01166 | CREB1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01167 | CREB1 miRNA 3'UTR clone | Inquiry |
| CDCB181021 | Rabbit CREB1 ORF clone (XM_008259049.1) | Inquiry |
| CDCH384094 | Rat CREB1 ORF clone(NM_134443.1) | Inquiry |
| CDCR041086 | Human CREB1 ORF clone (NM_004379.3) | Inquiry |
| CDCR041088 | Mouse Creb1 ORF clone (NM_133828.2) | Inquiry |
| CDCR050480 | Mouse Creb1 ORF clone (NM_009952.2) | Inquiry |
| CDCR050482 | Mouse Creb1 ORF clone (NM_001037726.1) | Inquiry |
| CDCR379515 | Rat Creb1 ORF Clone(NM_031017.1) | Inquiry |
| CDCS411755 | Human CREB1 ORF Clone (BC010636) | Inquiry |
Recent Research Progress
cAMP response element binding protein 1 (CREB1) is a well characterized transcription factor belonging to the basic ieucine zipper (bZIP) family. As a transcriptional activator, CREB1 binds to a conserved cAMP-response element (CRE) on the promoter and mediates transcriptional responses to various stimuli, including neurotransmitters, hormones, membrane depolarization, and growth and neurotrophic factors, thereby acting as a mediator between different signal pathways and the downstream target genes transcription. Interestingly, there is increasing evidence that CREB1 has potential carcinogenic functions and plays a key role in carcinogenesis and cancer progression.
CREB1 and CRC
CREB1 acts as a transcription factor for the ribonucleotide reductase M2 (RRM2) gene in human colorectal cancer (CRC). CREB1 directly binds to the promoter of the RRM2 gene and induces its transcriptional activation. Knockdown of CREB1 reduced the expression of RRM2 at mRNA and protein levels. Furthermore, knockdown of RRM2 attenuated CREB1-induced aggressive phenotypes of CRC cells in vitro and in vivo. A decrease in disease survival rate was observed in CRC patients with high expression levels of CREB1 or RRM2. The results indicate that CREB1 is a key transcription factor of RRM2, which promotes tumor aggressiveness and suggests a significant correlation between CREB1 and RRM2 in CRC specimens. These may offer the possibility that CREB1 and RRM2 can be used as biomarkers or targets for CRC diagnosis and treatment.
CREB1 and GC
Gastric cancer (GC) is the fourth most common cancer in the world and the second leading cause of cancer-related mortality in humans. The expression of miR-122 was significantly reduced in GC tissues and cell lines, and the decrease in expression was significantly associated with the invasive clinic pathological features of the patient. Moreover, overexpression of miR-122 significantly inhibited proliferation, migration and invasion in GC cell lines. Furthermore, CREB1 was identified as a direct target of miR122 and its expression was inversely correlated with miR-122 expression in GC tissues. Overexpression of CREB1 rescued the inhibitory effect of miR-122 on proliferation, migration and invasion of GC cells. Furthermore, miR-122 has been demonstrated miR-122 inhibited GC tumor genesis in vivo by repressing CREB1 expression. These findings suggest that miR-122 may function as a tumor suppressor in GC and could serve as a promising candidate for therapeutic applications regarding GC treatment.
CREB1 and glioma
Glioma originates from glial cells in the brain, accounting for about 45% of all intracranial tumors. The characteristic of glioma is invasive growth, as well as there is no obvious boundary between normal brain tissue and glioma tissue, so it is difficult to resect completely with worst prognosis. The metabolism of glioma follows the Warburg effect. Previous studies have shown that GLUT1, as a carrier of glucose transporters, affected the Warburg effect. Related studies have demonstrated that CREB1 protein regulates the expression of GLUT1, thus mediating glucose transport in cells. Recent experiments have revealed that the CREB1 can affect the glucose transport of glioma cells by regulating the expression of GLUT1, which control the metabolism of glioma and affects the progression of glioma.
In addition, related studies have shown that CREB1 is associated with a variety of diseases, such as major depression (MDD), diabetes. In conclusion, CREB1 plays an important role in a variety of diseases and mechanisms of cancer development. Therefore, further study of the function of CREB1 will provide new insights into the mechanisms of various diseases and have great potential for future clinical treatment.
References: